Amgen 2011 Annual Report Download - page 48

Download and view the complete annual report

Please find page 48 of the 2011 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 184

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184

The following table is a selection of certain of our product candidates by phase of development in our
therapeutic areas of focus as of February 10, 2012, unless otherwise indicated. Each target indication for product
candidates in phase 3 is listed separately. Additional product candidate (pipeline) information can be found on
our website at http://www.amgen.com. (This website address is not intended to function as a hyperlink, and the
information contained on our website is not intended to be a part of this filing.)
Molecule Disease/Condition Therapeutic Area
Phase 3 Programs
AMG 386 Ovarian cancer Hematology/Oncology
Aranesp®(darbepoetin alfa) Myelodysplastic syndromes Hematology/Oncology
Aranesp®(darbepoetin alfa) Anemia in heart failure Nephrology
Ganitumab Pancreatic cancer Hematology/Oncology
Motesanib First-line non-small cell lung cancer Hematology/Oncology
Prolia®(denosumab) Male osteoporosis Bone Health
Sensipar®/Mimpara®(cinacalcet) Cardiovascular disease in patients with secondary
hyperparathyroidism and chronic kidney disease undergoing
maintenance dialysis
Nephrology
Sensipar®/Mimpara®(cinacalcet) Post renal transplant Nephrology
Talimogene laherparepvec Malignant melanoma Hematology/
Oncology
Vectibix
®
(panitumumab) — US Only
First- and second-line colorectal cancer Hematology/Oncology
XGEVA®(denosumab) Delay or prevention of bone metastases in prostate cancer Hematology/Oncology
XGEVA®(denosumab) Delay or prevention of bone metastases in breast cancer Hematology/Oncology
Phase 2 Programs
AMG 145 Hypercholesterolemia Cardiovascular
AMG 151 Type 2 diabetes General Medicine
AMG 386 Various cancer types Hematology/Oncology
AMG 785 Bone-related conditions, including postmenopausal osteoporosis and
fracture healing
Bone Health
AMG 827 Inflammatory diseases Inflammation
AMG 888 Various cancer types Hematology/Oncology
Prolia®(denosumab) Rheumatoid arthritis Inflammation
Ganitumab Various cancer types Hematology/Oncology
Nplate®(romiplostim) Chemotherapy-induced thrombocytopenia Hematology/Oncology
Omecamtiv mecarbil Heart failure Cardiovascular
Rilotumumab Various cancer types Hematology/Oncology
Vectibix®(panitumumab) Locally advanced head and neck cancer Hematology/Oncology
XGEVA®(denosumab) Giant cell tumor of the bone Hematology/Oncology
Phase 1 Programs
AMG 139 Inflammatory diseases Inflammation
AMG 157 Asthma Inflammation
AMG 167 Bone-related conditions Bone Health
AMG 181 Inflammatory diseases Inflammation
AMG 208 Various cancer types Hematology/Oncology
AMG 319 Hematologic malignancies Hematology/Oncology
AMG 337 Various cancer types Hematology/Oncology
AMG 557 Systemic lupus erythematosus Inflammation
AMG 579 Neuroscience General Medicine
AMG 729 Autoimmune diseases Inflammation
AMG 745 Muscle-wasting disorders General Medicine
AMG 747 Neuroscience General Medicine
AMG 761 Asthma Inflammation
AMG 780 Various cancer types Hematology/Oncology
AMG 811 Systemic lupus erythematosus Inflammation
AMG 820 Various cancer types Hematology/Oncology
AMG 876 Type 2 diabetes General Medicine
AMG 900 Various cancer types Hematology/Oncology
Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.
Phase 2 clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease
or condition under study.
Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or
condition under study.
32